Featuring articles on lung-cancer screening in the NELSON trial, ribociclib and fulvestrant in metastatic breast cancer, vitamin D in pregnancy and asthma, treatment thresholds for neonatal hypoglycemia, and CAR-NK cells in anti-CD19 lymphoid tumors; a review article on placebo and nocebo effects; a Clinical Problem-Solving describing a rapid change in pressure; and Perspective articles on altruism in Extremis, on abuses of FDA regulatory procedures, and on joining forces against delirium.
“This is the fourth time in the last two years we’ve had to activate our hospital’s emergency operations plan for a major drug shortage,” Dr. Biddinger told NBC News. “It’s almost unfathomable in modern medicine. I never thought we would get to a point in the U.S. healthcare system where we wouldn’t have essential medicines to be able to treat patients.”
Drug shortages are increasing and lasting longer, according to an FDA report published Oct. 29. Of 163 drugs running low in 2013-17, over 62 percent were due to manufacturing or product quality problems.
Hospitals nationwide are facing shortages of crucial, lifesaving drugs, with 116 drugs currently running low, according to the FDA and cited byNBC News.
Boston-based Massachusetts General Hospital is a prime example, getting as close as two weeks away from canceling a lifesaving cardiac surgery due to a lack of herapin, a blood-thinner, according to Paul Biddinger, MD, chief of the division of emergency preparedness at Massachusetts General Hospital.